Indinol 300 mg + Epigallate 0.5 g N120x2 capsules

Who is prescribed Epigallate?

Most often, the drug Epigallate is prescribed for simultaneous use with indinol (which also has an inexpensive analogue, Indole-3 Carbinol) for the treatment of female pathologies - uterine fibroids, mastopathy, etc. This expensive medication is recommended to be taken for at least six months.

The main active ingredient of Epigallate is epigallocatechin gallate. It is a type of green tea catechins. Theoretically, the required amount of this substance can be obtained by drinking several cups of fresh infusion of tea leaves. But the fact is that catechins from the drink are not fully absorbed. That is why patients are prescribed medications containing the substance in the required dosage.

Publications in the media

I.S. SIDOROVA, head of the department, corresponding member of the Russian Academy of Medical Sciences A.L. UNANYAN, Associate Professor of the Department, Doctor of Medical Sciences N.V. KARASEVA, postgraduate student of the department of the Department of Obstetrics and Gynecology, FPPOV MMA named after. I. M. Sechenova

Uterine fibroids and adenomyosis are among the most common gynecological diseases after inflammatory processes. During preventive examinations, uterine fibroids are first detected in 1-5% of subjects, among gynecological patients - up to 30-35%. Endometriosis occurs in women of any age, regardless of social status and ethnicity. According to some scientists, the incidence of genital endometriosis ranges from 12 to 50%. The frequency of co-occurrence of uterine fibroids and adenomyosis is quite high and ranges from 35 to 80%.

An urgent task of gynecology is organ-preserving treatment of patients with uterine fibroids and adenomyosis. The current therapy with hormonal drugs for uterine fibroids and adenomyosis has a number of significant drawbacks. After cessation of hormonal treatment, most patients experience a relapse of clinical symptoms. The severity of side effects and the large number of contraindications to hormonal therapy also deserve attention.

As a result of numerous studies of hormonal status and hormone receptors in uterine fibroids, ambiguous results have been obtained, indicating the heterogeneity of fibroids. Currently, the role of other, previously unknown factors in the genesis of the combination of uterine fibroids and adenomyosis has been proven, namely: disruption of the processes of apoptosis, proliferation, neoangiogenesis, and stromal formation in the development of these diseases. The literature describes substances with antiproliferative, antiangiogenic and proapoptotic effects, in particular indole-3-carbinol and epigallocatechin-3-gallate. Indole-3-carbinol has powerful antitumor activity, pathogenetically affecting the main links in the development of hyperplastic processes in the body. Epigallocatequin-3-gallate is one of the representatives of catechins, has the strongest antioxidant activity, comparable to setocofferol, as well as anti-inflammatory, antiproliferative and antiangiogenic effects.

The effects of these drugs have been studied in various pathological models in studies by scientists from different countries. However, there is not yet enough scientific research to study the effects of these drugs in the combination of uterine fibroids and adenomyosis. In this regard, a clinical study was conducted on the effectiveness of drugs containing indole-3-carbinol and epigallocatechin-3-gallate in patients with a combination of uterine fibroids and adenomyosis.

The study included 92 patients aged 35–49 years (mean age 42±7 years), who had no indications for surgical treatment and were prescribed hormonal therapy. The patients were divided into 2 groups. The first included 47 people who were prescribed gonadotropin-releasing hormone (GnRH) agonists: buserelin depot 3.75 mg/month intramuscularly or triptorelin 3.75 mg/month intramuscularly for 6 months. The second group included 45 people who received therapy with GnRH agonists and drugs containing indole-3-carbinol 400 mg/day (the drug Indinol 2 capsules 2 times a day with meals) and epigallocatechin-3-gallate 200 mg/day days (Epigallate, 2 capsules 2 times a day with meals) for 6 months. The patients were concerned about general weakness and increased fatigue (19.6%). The predominant symptoms were heavy and prolonged menstruation (72.8%), painful menstruation (41.3%), perimenstrual bleeding (38%), pain in the lower abdomen (13%), acyclic bleeding (9.8%), dyspareunia ( 16.3%), dysuric symptoms (12%). Of the 61 (66.3%) patients of reproductive age with a combination of uterine fibroids and adenomyosis, there was primary (2.2%) or secondary (3.3%) infertility. The duration of combined uterine disease ranged from several months to 14 years (on average 7.6±1.5 years). During therapy with GnRH agonists, a noticeable decrease in uterine volume was observed in all patients of the first group. The maximum reduction of the uterus was 42-45% of the initial volume by the end of the 6-month course of treatment. However, after the end of the course of treatment, growth of the uterus was noted, and 6 months after the end of treatment, the volume of the uterus reached its previous size. The same trend was observed when studying the volume of the dominant node and assessing the thickness of the uterine wall with adenomyosis.

When using GnRH agonists, side effects were observed: “hot flashes” to the head, neck, and body were noted in most patients and did not depend on the drug used, occurring in 75-80% of patients. Patients also noted headaches (24%), irritability (18%), sweating (17%), sleep disturbances (11%), dry mucous membranes and discomfort during sexual activity (10%), decreased libido (10%), swelling legs, face (5%). There were no complications or severe side effects that could lead to discontinuation of the drug. We observed a slightly different clinical picture in women of the second group. In this group of patients, a significant gradual decrease in uterine volume was also observed. In the case of simple fibroids, after 3 months the volume of the uterus decreased by 32%, after 6 months - by 57%. In the case of proliferating fibroids, after 3 months a decrease in the volume of the uterus was diagnosed by 43.5%, after 6 months - by 59.5%, which coincided with the dynamics of the decrease in the volume of the uterus in patients of the first group. But after discontinuation of the drugs, the growth of the uterus was not as significant as in patients of the first group. The same trend was noted when assessing the dynamics of the dominant fibroid node and the thickness of the uterine wall with adenomyosis. It should be noted that side effects in the second group of patients were associated with the use of GnRH agonists. None of the patients reported any side effects associated with taking Indinol or Epigallate.

conclusions

In connection with the study, we can conclude that the use of GnRH agonists as an independent method in patients with preserved menstrual function is not effective enough. And the addition to treatment of drugs containing indole-3-carbinol (Indinol) and epigallocatechin-3-gallate (Epigallate), which affect the molecular mechanisms of uterine fibroids and adenomyosis - apoptosis, proliferation, neoangiogenesis, has shown good clinical efficacy in the treatment of a combination of uterine fibroids and adenomysis.

Thus, new ways of pharmacological correction of uterine fibroids and adenomyosis have been identified. The use of the drugs Indinol and Epigallate, which influence the main pathogenetic mechanisms of the development of fibroids and adenomyosis, opens a new direction in the treatment of these diseases - targeted therapy. Such therapy should become a priority for practitioners in the treatment of uterine fibroids and adenomyosis.

How to replace Epilagat on iHerb?

A safe and effective analogue of Epigallate is green tea extract EGCg from Now Foods. You can purchase it in the iHerb online store. The dietary supplement contains epigallocatechin gallate, which minimizes the risk of developing breast cancer, as well as other diseases of the female genital area.

Green Tea Extract EGCg on iHerb

Epigallate and analogues on iHerb

Let's compare epigallate and analogues on iHerb, for example, EGCg, green tea extract from Now Foods. Epigallate is usually prescribed for joint use with indinol in the treatment of female diseases - mastopathy, uterine fibroids and some others. Treatment is expensive. Usually a course of at least 6 months is prescribed.

Indole-3-carbinol and epigallocatechin gallate are active phytochemicals that are present in certain plants and are the main active ingredients in these preparations. We have already discussed in detail the presence of indole-3-carbinol in food products.

Epigallocatechin gallate is a type of green tea catechin that can in principle be obtained by drinking a certain number of cups of green tea, but the method is very unreliable and questionable. Epigallate is a dietary supplement containing 45 mg of pure epigallocatechin gallate. The price is steep. In my opinion, there is no point in overpaying for a supplement if you can buy an identical one much cheaper.

Epigallate and analogues: comparison table

As you can see from the table, a daily dose of treatment with EGCg, green tea extract from Now Foods will cost ten times less. A six-month course of treatment with this drug costs 1,041 rubles.

The dosage of one capsule of epigallate is much lower (45 mg versus 200 mg), it is taken two capsules twice a day. For a course of treatment you need to buy 6 packages of 120 capsules, which is already 11,244 rubles. The difference is 10 thousand rubles!

Instructions for use EGCg

The manufacturer recommends taking 1 capsule of EGCg daily with meals. One package contains 90 or 180 capsules. This is enough for the entire course of treatment, which usually lasts three months.

Important! The period of therapy can be increased only in consultation with the doctor. The specialist will assess the patient’s condition, the presence of chronic diseases and other significant factors. Based on all this data, a decision will be made on the possibility of undergoing a second course of treatment.

Thanks to the soluble capsule shell, catechins pass through the digestive tract, end up in the intestines and from there begin to be actively absorbed into the circulatory system. Once in the body, these substances stop pathological growth and cell division in the area of ​​the reproductive organs of women, strengthen the immune system, and eliminate chronic fatigue.

INDINOL No. 120 CAPS.+EPIGALLATE No. 120 CAPS. (No. 240)

Cost in pharmacies: Biomedservice on the street. Ivan Alekseeva, 6, tel. 243-109, cell. 8-913-632-69-45 3645 rub. Biomedservice st. Dekabristov, 45. (3812) 31-05-64, 533-573, 8-913-649-42-83, 3740 rub. Instructions for use:

Indinol
Composition:
Ingredient composition for 1 capsule 300 mg:

Active ingredients.

Each capsule contains at least 90 mg of indole-3-carbinol.

Pharmacological properties

. Indinol is a universal corrector of pathological hyperplastic processes in the organs and tissues of the female reproductive system (breast, endometrium, myometrium, cervix, ovaries). Normalizes the balance of estrogen in the body and suppresses their negative stimulating effect, and also blocks other (hormone-independent) mechanisms that activate pathological cellular growth in the tissues of the mammary gland and uterus. It has the ability to cause selective death of transformed cells with abnormally high proliferative activity.

Recommendations for use

. Indinol is recommended as a dietary supplement to food - an additional source of indole-3-carbinol. Indinol is recommended to be used:

• for the prevention of fibrocystic mastopathy and as part of its complex treatment, as well as for the correction of the functional states of the mammary glands caused by this pathology;
• in combination with the dietary supplement Epigallat in the complex therapeutic treatment of endometriosis, adenomyosis, uterine fibroids and endometrial hyperplasia without atypia, as well as for the prevention of relapse of these diseases after surgical treatment;
• in the complex treatment of genital diseases in women associated with the human papillomavirus: cervical dysplasia (intraepithelial cervical neoplasia), anogenetic condylomatosis.

Directions for use and recommended doses

.
For women suffering from fibrocystic mastopathy, Indinol is recommended to be taken orally, 1 capsule per day with meals for 2-3 weeks. As part of combination therapy (endometrial hyperplasia without atypia, endometriosis, adenomyosis, uterine fibroids), Indinol is recommended to be taken orally in combination with the dietary supplement Epigallat (1 capsule + 1 capsule) with meals for 2-3 weeks. Longer use is possible on the recommendation of a doctor. For genital diseases associated with the human papillomavirus, Indinol is recommended to be taken orally, 1 capsule once a day, in combination with immunomodulator drugs used as standard treatment for these diseases. In this case, both sexual partners must undergo treatment. Side effect
.
According to preclinical and clinical studies of the drug, Indinol is well tolerated, without causing side effects in therapeutic doses. Contraindications.
Indinol is contraindicated in case of individual intolerance to the components of the drug.
Not recommended for pregnant and lactating women, as well as for persons taking medications that reduce gastric acidity. Not a medicine. Does not contain GMOs. Release form
.
Capsules in polymer jars with a lid, 60, 120 capsules per jar. It is allowed to pack the can in a consumer pack. Storage conditions
. Store in a dry place at room temperature.

Best before date. 2 years.

Epigallate®

blocks the growth of new vessels in affected tissues, disrupts the blood supply to pathological foci. When used in combination with Indinol®, it helps to inhibit the growth of uterine fibroids, endometrial hyperplasia, reduce foci of endometriosis, and prevent relapses (re-development of the disease) after surgical treatment and hormonal therapy.

The method of combination therapy Epigallate® + Indinol® has been used in leading clinical and scientific centers in Russia since 2006. Over the past three years alone, more than 70 thousand women have found this health formula for themselves.

Recommendations for use.

Composition per 1 capsule 500 mg.

• Active ingredients: epigallocatechin-3-gallate at least 45 mg and mineral premix.

Pharmacological properties:

The active substances of Epigallate have multiple etiopathogenetic effects in relation to hyperplastic processes of the reproductive system. Suppresses pathological growth and cell division in organs and tissues of the female reproductive system caused by non-hormonal stimuli. Reduces the invasive activity of endometrial cells, and also causes selective death (apoptosis) of cells with increased proliferative activity. Epigallate® has a pronounced antiangiogenic effect (suppresses the pathological growth of new vessels) and thus prevents the growth of tumors. It is an effective anti-inflammatory agent, suppressing the activity of type 2 cyclooxygenase, prostaglandins and the synthesis of proinflammatory cytokines, and in addition, enhances the effect of antibiotics (tetracyclines, β-lactams) and increases the sensitivity of resistant microorganisms to the action of antibacterial agents. It has a pronounced antioxidant effect, neutralizing the formation of free radicals.

Recommendations for use:

Adults: 2 capsules 2 times a day with meals. Duration of treatment: 6 months.

Side effects:

According to preclinical and clinical studies, Epigallate® is well tolerated, without causing side effects in therapeutic doses.

Contraindications:

Individual intolerance to components; Not recommended for people taking medications that reduce gastric acidity, as well as for pregnant and lactating women. It is recommended to consult a doctor before use. Not a medicine.

Release form:

Capsules in polymer jars with a lid, 120 capsules per jar.

Consult your physician before use.
The description of the drug on the website does not constitute instructions for the use of Epigallate. Other drugs from the group Drugs for the treatment of mastopathy, uterine fibroids and other hormone-dependent diseases of the female genital area

Side effects and contraindications

The EGCg dietary supplement is well tolerated and very rarely causes allergic reactions. In its production process, no components of animal origin, milk, soy, seafood, gluten, or nuts are used. EGCg does not contain artificial flavors, colors, or sugar substitutes.

Before you start taking EGCg, you need to consider certain restrictions:

• during pregnancy and lactation, use of the supplement is possible only under the supervision of a specialist;
• if you have chronic diseases, including liver failure, you should also consult your doctor;
• The dietary supplement is intended only for adult patients.

EGCg is an inexpensive but effective analogue of Epigallate. It improves the general condition of a woman, eliminates pathological processes in the reproductive system. You can purchase EGCg from the trusted manufacturer of dietary supplements Now Food in the American online store IHerb.